TFEB and cancer: Zhitomirsky and Assaraf demonstrated that nanomolar doses of weakly basic drugs stimulate cancer cells to increase lysosome numbers through Transcription Factor EB (TFEB)-mediated biogenesis, effectively expanding the lysosomal “sink” and compounding multidrug resistance (MDR) over time [12,45,46].